Industry Partner perspectives

In this section you will find all the industry partner perspectives published on this website. Whether it’s an expert opinion, an industry partner's viewpoint on device development, or promoted content you can find it here. This content is considered to be of educational value and is not intended as advertising. Publication on this website does not equal endorsement.

Filter By

46 results

ACURATE neo™ Aortic Valve System shows safety & efficacy results comparable to SAPIEN 3

Multi-centre propensity-matched comparison study1 between ACURATE neo Aortic Valve System and Edwards SAPIEN 3 Transcatheter Heart Valve, published in October’s edition of the Journal of the American College of Cardiology (JACC) shows comparable procedural outcomes:

Observational, propensity-matched multicenter comparison of ACURATE neo and SAPIEN 3 from 3 high volume centers in Germany (DHZ Munich, UK Regensburg, Kerckhoff Klinikum Bad Nauheim)1,121 consecutive patients between Jan. 2014 and Jan. 2016 with symptomatic, severe stenosis of the native aortic valve treated with transfemoral TAVI using ACURATE neo (n = 311) or SAPIEN 3 (n = 810)To increase statistical power, a 1-to-2 nearest neighbor matching was used to identify 2 control cases treated with SAPIEN 3 (n = 622) for each case treated with ACURATE neo (n = 311)Endpoints: device failure and early safety composite endpoint at 30 days according to VARC-2 criteria

View full JACC publication

Biodegradable polymer Everolimus-eluting SYNERGY stents in elderly patients with coronary artery disease (SENIOR): a randomised single-blind trial

EWOLUTION 1 year follow up results

The prospective study confirms the safety and efficacy of the WATCHMAN Left atrial appendage closure device in stroke risk reduction in patients with high risk of stroke, bleeding and multiple co-morbidities.

SOURCE 3 post-approval registry—One-year outcomes in 1,946 TAVI patients with a 3rd generation balloon transcatheter heart valve

Speaker: O. Wendler

At 1 year, patients treated via the transfemoral access route had a high survival rate (88.2 percent) and a low disabling stroke rate (1.1 percent).Patients experienced a low rate (2.7 percent) of moderate paravalvular leak and no severe paravalvular leak.

Explore the SOURCE 3 Registry: Real-World Evidence With the Edwards SAPIEN 3 Transcatheter Heart Valve

At EuroPCR 2017, new one-year data from a post-approval study of the Edwards SAPIEN 3 valve demonstrated positive patient outcomes, including high survival rates, low rates of stroke, and low rates of paravalvular leak.

The majority of patients in the SOURCE 3 Registry were treated via transfemoral access, and more than half were treated under conscious sedation. SOURCE 3 patients were enrolled at 80 centres across 10 countries between July 2014 and October 2015, and will continue to be followed for five years post-TAVI.

Growing clinical evidence with the ACURATE neo™ TAVI System

Summary: Join S. Redwood, S. Toggweiler and H. Moellmann as they

Discuss the advantages of the ACURATE neo™ intuitive and predictable implantation procedure with a unique “top-down” deploymentHighlight the latest clinical data from the 1-Year follow-up of the SAVI-TF 1000 global registry1

LOTUS™ Valve PPM Rate: New data shows a downward trend in Permanent Pacemaker Rate (PPM)

The LOTUS™ Valve System is a controlled mechanical expansion TAVI technology, designed to provide unmatched freedom from PVL, precise delivery and deployment, and predictable results.

Case Study: Complex Left Main with Two Sidebranches

Authors :

Dr. Nicolas Boudou

Initial Experience of Bioabsorbable Polymer Everolimus-Eluting Synergy Stents in High-Risk Patients Undergoing Complex PCI With Early Discontinuation of Dual-Antiplatelet Therapy

Authors :

Rebecca L. Noad, MB, PhD; Colm G. Hanratty, MD; Simon J. Walsh, MD

Watchman™ Ewolution prospective registry - 3 months results & clinical impact

Authors :

Prof. Martin W. Bergmann